AstraZeneca partners with Oracle for AI-driven clinical trials

Oct 20 (Reuters) - AstraZeneca ‌said on ​Tuesday ​that it is working with Oracle to use AI and real-world data ‌to identify eligible patients for clinical trials ⁠and monitor safety signals, among other measures, as ‌the drugmaker looks to ‌improve clinical research.

• The collaboration will combine AstraZeneca's drug development expertise with Oracle's AI ​and healthcare data capabilities to support patient matching and research

• Initial work will focus ⁠on cancer, cardiovascular, respiratory, immunology and rare diseases, and could ​also support earlier diagnosis of serious diseases

• The first project will support hypertension ​research in Abu Dhabi ‌in partnership with UAE-based healthcare firm M42

• Patient recruitment remains one of ⁠the biggest challenges in clinical research, with delayed enrolment often extending trial timelines and increasing development ⁠costs

• Incorrect trial designs have also hurt AstraZeneca in ​the past, with delays on its breast cancer drug and nerve disorder treatment failure causing some worries

• ‌AstraZeneca is seeking to expand its medicine portfolio as it targets over $80 ‌billion in annual revenue by 2030, and ⁠works to address industry ‌bottlenecks in ​drug development

(Reporting by Atharva Singh and Pushkala Aripaka in Bengaluru; Editing by Priyanka ‌G)

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Ryanair optimistic Boeing MAX 10 certification will be done in October
• South Korea to pull more Ukraine embassy staff after POW dispute
• Half of OVHcloud capacity is available, AI model launching in early 2027, CEO says